HONG KONG – With the advantage of an English-speaking population, precision manufacturing capabilities and courts dedicated to solving intellectual property matters, Malaysia is quickly emerging as a launch pad for biopharmaceutical companies looking to enter the Asian market and regional companies aiming to expand.